

Supplementary Table 1. Baseline characteristics of the overall population and STEMI and NSTEMI groups in the IPTW-adjusted data

Characteristic	Overall population			STEMI group			NSTEMI group		
	Early presenters (n = 2,871)	Late presenters (n = 2,889)	p value	Early presenters (n = 1,387)	Late presenters (n = 1,405)	p value	Early presenters (n = 1,484)	Late presenters (n = 1,484)	p value
Male patients	2,043 (71.2)	2,066 (71.5)	0.880	1,047 (75.5)	1,070 (76.2)	0.836	997 (67.2)	996 (67.1)	0.988
Age, yr	64.11 ± 11.56	64.43 ± 12.05	0.676	62.83 ± 11.92	63.34 ± 12.85	0.704	65.30 ± 11.09	65.45 ± 11.17	0.839
Age ≥ 75 yr	596 (20.8)	619 (21.4)	0.769	258 (18.6)	273 (19.4)	0.820	338 (22.8)	346 (23.3)	0.845
EMS utilization	400 (13.9)	418 (14.5)	0.860	249 (17.9)	246 (17.5)	0.936	152 (10.2)	172 (11.6)	0.635
Killip III–IV	432 (15.0)	392 (13.6)	0.400	233 (16.8)	203 (14.5)	0.418	199 (13.4)	188 (12.7)	0.743
BMI ≥ 25 kg/m ²	1,093 (38.1)	1,006 (34.8)	0.228	540 (39.0)	467 (33.3)	0.205	552 (37.2)	538 (36.3)	0.765
Previous history									
Hypertension	1,740 (60.6)	1,817 (62.9)	0.397	784 (56.6)	860 (61.2)	0.291	956 (64.4)	956 (64.5)	0.985
DM	2,279 (79.4)	2,373 (82.2)	0.188	1,060 (76.4)	1,140 (81.2)	0.156	1,219 (82.2)	1,233 (83.1)	0.725
Dyslipidemia	421 (14.7)	458 (15.9)	0.605	187 (13.5)	219 (15.6)	0.604	233 (15.7)	239 (16.1)	0.871
Prior IHD	491 (17.1)	460 (15.9)	0.580	176 (12.7)	163 (11.6)	0.728	315 (21.2)	297 (20.0)	0.670
Prior CVA	248 (8.6)	255 (8.8)	0.913	104 (7.5)	114 (8.1)	0.834	143 (9.7)	140 (9.5)	0.903
Smoking	1,644 (57.3)	1,606 (55.6)	0.546	843 (60.8)	831 (59.1)	0.708	801 (54.0)	775 (52.2)	0.596
Family history of IHD	169 (5.9)	199 (6.9)	0.571	75 (5.4)	105 (7.5)	0.487	95 (6.4)	94 (6.3)	0.981
HbA1c strata, %			0.215			0.777			0.093
< 6.5	551 (19.2)	637 (22.1)		247 (17.8)	286 (20.3)		304 (20.5)	351 (23.7)	
6.5–9.0	1801 (62.7)	1,672 (57.9)		854 (61.6)	825 (58.7)		947 (63.8)	847 (57.1)	
≥ 9.0	519 (18.1)	579 (20.0)		286 (20.6)	294 (21.0)		233 (15.7)	285 (19.2)	
LVEF, %	50.43 ± 11.40	51.05 ± 11.71	0.410	49.04 ± 10.47	50.40 ± 11.41	0.219	51.92 ± 12.04	51.67 ± 11.98	0.727
LVEF < 40%	477 (16.6)	437 (15.1)	0.366	247 (17.8)	209 (14.9)	0.264	230 (15.5)	228 (15.3)	0.939
Use of PCI	2,871 (100.0)	2,889 (100.0)	-	1,387 (100.0)	1,405 (100.0)	-	1,484 (100.0)	1,484 (100.0)	-
Femoral approach	1,861 (64.8)	1,862 (64.5)	0.898	1,077 (77.6)	1,06 (75.5)	0.602	784 (52.8)	801 (54.0)	0.704
GPIIb/IIIa inhibitors	400 (13.9)	341 (11.8)	0.215	273 (19.7)	221 (15.8)	0.198	127 (8.5)	120 (8.1)	0.786
Thrombus aspiration	656 (22.8)	621 (21.5)	0.581	510 (36.8)	474 (33.7)	0.483	145 (9.8)	147 (9.9)	0.965
Image-guided PCI	623 (21.7)	561 (19.4)	0.255	266 (19.2)	211 (15.0)	0.156	357 (24.0)	349 (23.5)	0.858
IRA			0.250			0.833			0.076
LMCA	67 (2.3)	73 (2.5)		26 (1.9)	23 (1.7)		41 (2.8)	49 (3.3)	
LAD	1,318 (45.9)	1,402 (48.5)		692 (49.9)	754 (53.7)		626 (42.2)	648 (43.7)	
LCX	495 (17.3)	390 (13.5)		117 (8.4)	109 (7.7)		378 (25.5)	281 (18.9)	
RCA	991 (34.5)	1,024 (35.5)		552 (39.8)	519 (36.9)		439 (29.6)	506 (34.1)	

Supplementary Table 1. Continued

Characteristic	Overall population			STEMI group			NSTEMI group		
	Early presenters (n = 2,871)	Late presenters (n = 2,889)	p value	Early presenters (n = 1,387)	Late presenters (n = 1,405)	p value	Early presenters (n = 1,484)	Late presenters (n = 1,484)	p value
ACC/AHA lesion types			0.498			0.598			0.653
B2/C lesion	2,517 (87.7)	2,494 (86.4)		1,254 (90.4)	1,248 (88.8)		1,263 (85.1)	1,247 (84.0)	
A/B1 lesion	354 (12.3)	394 (13.6)		133 (9.6)	157 (11.2)		221 (14.9)	237 (16.0)	
Initial TIMI flow grade			0.384			0.251			0.965
0–I	1,575 (54.9)	1,514 (52.4)		1,023 (73.7)	963 (68.6)		553 (37.2)	550 (37.1)	
II–III	1,296 (45.1)	1,375 (47.6)		364 (26.3)	442 (31.4)		931 (62.8)	933 (62.9)	
LMCA disease	149 (5.2)	139 (4.8)	0.685	52 (3.7)	39 (2.8)	0.435	97 (6.6)	100 (6.7)	0.911
MVD	1,659 (57.8)	1,655 (57.3)	0.857	751 (54.1)	733 (52.2)	0.678	908 (61.2)	922 (62.1)	0.775
Use of thrombolysis	27 (0.9)	23 (0.8)	0.761	27 (1.9)	23 (1.6)	0.751	0 (0.0)	0 (0.0)	-
Discharge medications									
Aspirin	2,867 (99.9)	2,886 (99.9)	0.727	1,386 (99.9)	1,405 (100.0)	0.315	1,482 (99.8)	1,481 (99.8)	> 0.999
P2Y12 inhibitors	2,865 (99.8)	2,886 (99.9)	0.357	1,385 (99.8)	1,403 (99.9)	0.993	1,480 (99.7)	1,484 (100.0)	0.085
Beta-blockers	2,472 (86.1)	2,514 (87.0)	0.592	1,201 (86.6)	1,223 (87.1)	0.875	1,270 (85.6)	1,291 (87.0)	0.483
RAS inhibitors	2,346 (81.7)	2,381 (82.4)	0.705	1,117 (80.5)	1,148 (81.7)	0.703	1,229 (82.8)	1,233 (83.1)	0.897
Statins	2,648 (92.2)	2,677 (92.7)	0.714	1,280 (92.3)	1,308 (93.1)	0.686	1,368 (92.2)	1,370 (92.3)	0.925

Values are presented as number (percentage) for categorical variables and mean $\pm$ standard deviation for continuous variables.

ACC/AHA, American College of Cardiology/American Heart Association; BMI, body mass index; CVA, cerebrovascular accident; DM, diabetes mellitus; EMS, emergency medical service; HbA1c, glycated hemoglobin; IHD, ischemic heart disease; IPTW, inverse probability of treatment weighting; IRA, infarct-related artery; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; MVD, multivessel disease; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; RAS, renin-angiotensin; RCA, right coronary artery; STEMI, ST-elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.